Join Cidara Therapeutics for a virtual R&D Day featuring key opinion leaders (KOLs) Fred Hayden, MD, FACP (University of Virginia School of Medicine) and Rick Bright, PhD (Pandemic Prevention Institute, The Rockefeller Foundation), who will join company management to discuss Cidara’s flu DFC, CD388, as a potential universal, once-per-flu season preventative of influenza.

Key topics will address the 2024-2025 influenza season in the northern hemisphere, the design and objectives of the Company’s ongoing Phase 2b NAVIGATE trial with updates on the statistical analysis plan to evaluate study efficacy results, the planned Phase 3 CD388 study design, a review of the competitive landscape and commercial opportunity for CD388, and the prospects for pandemic influenza.

A live question and answer session will follow the formal presentations.